A novel approach for preventing esophageal stricture formation: sphingosylphosphorylcholine-enhanced tissue remodeling.
Using a new class of intracellular 2nd messengers to prevent stricture formation after caustic ingestion, sphingosylphosphorylcholine (SPC) has a wide spectrum of activity in cell growth regulation and signal transduction. Caustic esophageal burns were created with 15% NaOH in an experimental rat model. Control group animals (n = 10) had esophageal burns with no treatment, whereas the SPC group (n = 10) had esophageal burns gavaged with SPC for 7 days. Efficacy of treatment was assessed in 28 days by contrast esophagograms, histopathologic evaluation, and biochemically by tissue hydroxyproline (OHP) content. Contrast esophagograms demonstrated that SPC significantly prevented stricture formation. Obvious collagen deposition was present in submucosa, muscularis mucosa, and muscular layers in the control group compared with the SPC group. The damage to the esophageal wall on histopathologic examination was significantly lower in the SPC group (p < 0.05). Tissue OHP contents were significantly lower in the SPC-treated group (3.0 +/- 0.1 microg/mg) compared with the control group (4.3 +/- 0.2 microg/mg) (p < 0.05). We conclude that SPC improves healing following caustic esophageal burns. Furthermore, SPC is effective in preventing caustic esophageal strictures. These effects of SPC occur through its proliferative and specifically its remodeling effects on wound healing.
Yagmurlu
Aydin
A
Department of Pediatric Surgery, Ankara University, School of Medicine, Gumus Cad. D-14.4 Konutkent-1 06530, Ankara, Turkey. yagmurlu@tr.net
Aksu
Burhan
B
Bingol-Kologlu
Meltem
M
Renda
Nurten
N
Altinok
Gulcin
G
Fitoz
Suat
S
Gokcora
I Haluk
IH
Dindar
Huseyin
H
D000818:Animals; D002057:Burns, Chemical / Q000150:complications; D002424:Caustics / Q000009:adverse effects; D003094:Collagen / Q000032:analysis; D003287:Contrast Media; D004195:Disease Models, Animal; D004940:Esophageal Stenosis / Q000517:prevention & control*; D004947:Esophagus / Q000000981:diagnostic imaging / Q000293:injuries / Q000473:pathology; D005260:Female; D006909:Hydroxyproline / Q000032:analysis; D009092:Mucous Membrane / Q000473:pathology; D009130:Muscle, Smooth / Q000473:pathology; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D015290:Second Messenger Systems / Q000502:physiology; D012972:Sodium Hydroxide / Q000009:adverse effects; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000502:physiology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
D002424:Caustics; D003287:Contrast Media; C005356:sphingosine phosphorylcholine; D010767:Phosphorylcholine; D012972:Sodium Hydroxide; D003094:Collagen; D013110:Sphingosine; D006909:Hydroxyproline